Thus, our study provided a potential biomarker dataset for NSCLC prognosis and suggested that TOP2A, in particular, may be a valuable survival biomarker to improve prognostic efforts and possibly guide new therapeutic developments for NSCLC. The gene discussed is TOP2A; the disease is non-small cell lung carcinoma.